Entera Bio
ENTX
22 hedge funds and large institutions have $17.7M invested in Entera Bio in 2025 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
16% more funds holding
Funds holding: 19 → 22 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.33% less ownership
Funds ownership: 22.47% → 20.14% (-2.3%)
9% less capital invested
Capital invested by funds: $19.4M → $17.7M (-$1.75M)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$1.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$54.2K |
| 3 |
Renaissance Technologies
New York
|
+$46.1K |
| 4 |
Jane Street
New York
|
+$38.9K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$35K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.91M |
| 2 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$144K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$99.6K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
-$94.5K |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$71.9K |
ENTX Hedge Fund Activity: Q3 2025 in Review
22 of the 7,629 institutional investors tracked by Wall St. Rank reported a position in Entera Bio (ENTX) for Q3 2025, worth a combined $17.7M — down 9% from $19.4M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ENTX positions and 1 closed out — a net gain of 3 holders — while 5 added to existing stakes and 7 trimmed.
The largest buyer was Marshall Wace, opening a new position worth an estimated $1.2M. The largest seller was Point72 Asset Management, cutting an estimated $2.91M.
- 22 institutional investors held Entera Bio (ENTX) as of Q3 2025, up from 19 in Q2 2025.
- Funds reported $17.7M of Entera Bio stock for Q3 2025, down 9% quarter-over-quarter.
- 4 funds opened new Entera Bio positions in Q3 2025 and 1 closed out, a net change of +3 holders.
- The largest Entera Bio buyer in Q3 2025 was Marshall Wace, an estimated $1.2M added.
- The largest Entera Bio seller in Q3 2025 was Point72 Asset Management, an estimated $2.91M sold.
Based on aggregated 13F filings for Q3 2025.